Full information can be found in the Summary of Product Characteristics.
Voltarol Back & Muscle Pain Relief 1.16% Gel, Voltarol Max Strength Pain Relief 2.32% Gel, Voltarol Joint & Back Pain Relief 2.32% Gel, Voltarol Osteoarthritis Joint Pain Relief 1.16% Gel (diclofenac diethylammonium). Indications Local symptomatic relief of pain and inflammation in trauma of the tendons, ligaments, muscles and joints e.g. due to sprains, strains and bruises, and localised forms of soft tissue rheumatism. Osteoarthritis and Max Strength Gel only: Relief of pain of non-serious arthritic conditions. Dosage and method of use Adults and children aged 14 years and over. Gently rub 2-4 g into skin of affected site. If symptoms worsen or do not improve within 7 days, seek medical advice. For children aged 14 years and over, if the product is required for more than 7 days for pain relief or if the symptoms worsen the patient/ parents of the adolescents is/are advised to consult a doctor. Back & Muscle Gel: Apply 3-4 times daily for up to 14 days. Leave at least 4 hours between applications. No more than 4 applications in 24 hours. Not to be used for more than 14 days unless recommended by a doctor. Maximum daily dose 16 g. Max Strength Pain Relief: Apply 2 times daily (morning and evening) for up to 21 days. Maximum daily dose 8 g. Not for use for longer than 21 days unless recommended by doctor. Joint & Back Pain Relief: Apply 2 times daily (morning and evening) for up to 14 days. Maximum daily dose 8 g. Not for use for longer than 14 days unless recommended by doctor. Osteoarthritis Gel: Apply 3-4 times daily for up to 21 days. Maximum daily dose 16 g. Not for use for longer than 21 days unless recommended by doctor. Consult doctor if more than two major joints affected. Contraindications Patients whose asthma, angioedema, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs. Hypersensitivity to diclofenac, aspirin, other NSAIDs or excipients. Third trimester of pregnancy. Osteoarthritis and Back & Muscle Gel: Children under 14 years. Precautions Use at higher dosage/large amounts over large areas of skin and / or over a prolonged period may lead to systemic adverse events. Do not smoke and avoid naked flames. Avoid excessive exposure to sunlight to reduce incidence of photosensitivity. Apply only to intact, nondiseased skin. Do not use with occlusion. Avoid ingestion or contact with eyes or mucous membranes. Caution in patients with previous or active peptic ulceration; suffering from/previous history of asthma or allergic disease. Discontinue use if skin rash develops. Caution with concomitant use of other diclofenac products or systemic NSAIDs. Joint & Back Pain Relief and Max Strength Gel contain propylene glycol, which may cause mild skin irritation, and butylhydroxytoluene, which may cause local skin reactions or irritation to the eyes and mucous membranes. Back & Muscle Gel and Osteoarthritis Gel contain propylene glycol and benzyl benzoate, which may cause mild localised skin irritation. Side effects See SPCs for full details. Common: Rash, eczema, erythema, dermatitis (including dermatitis contact), pruritus. Product licence number, legal category, pack size and RSP (excl. VAT) Back & Muscle Gel: PL 44673/0156 (GSL) 30 g £5.41, 50 g £7.96, 100 g £12.75. 100 g (no mess) £14. Max Strength Pain Gel: PL 44673/0154 (P), 30 g £7.49, 50 g £10.57, 100 g £15.57. Joint & Back Pain Gel: PL 44673/0160 (GSL), 30 g £7.49, 50 g £10.57. Osteoarthritis Gel: PL 44673/0155 (P), 30 g £5.41, 50 g £7.96, 100 g £10.71. PL holder Gels: Haleon UK Trading Limited, The Heights, Weybridge, KT13 0NY, U.K. Date of preparation: January 2026.
Full information can be found in the Summary of Product Characteristics.
Panadol Advance 500 mg Tablets (Paracetamol). Indications: For the treatment of most painful and febrile conditions, including symptomatic relief of pain due to nonserious arthritis. Dosage and administration: Adults and children, 16 years and over: One or two tablets up to four times daily as required. Max. 4 doses in 24 hours. Children 10-15 years: One tablet up to four times daily as required. Max. 4 doses in 24 hours. Do not give to children for more than 3 days without a doctor’s advice. Doses should not be repeated more frequently than every 4 hours. Children under 10 years: Not suitable. Contraindications: Known hypersensitivity to ingredients. Warnings and Precautions: Do not use with any other paracetamol-containing products. Those with renal or hepatic impairment should seek advice before use. Patients with persistent headaches or those with non-serious arthritis who need to take painkillers every day should consult a doctor. Caution, regarding paracetamol, if used at therapeutic doses for a prolonged period or administered concomitantly with flucloxacillin due to increased risk of high anion gap metabolic acidosis (HAGMA), particularly in patients with severe renal impairment, sepsis, malnutrition and other sources of glutathione deficiency (e.g. chronic alcoholism). If suspected, discontinue use promptly and monitor closely, including measurement of urinary 5-oxoproline. If symptoms persist seek medical advice. Side effects: Very rare: Thrombocytopenia, agranulocytosis, anaphylaxis, cutaneous hypersensitivity reactions including skin rash, and angioedema. Serious skin rashes, bronchospasm and hepatic dysfunction. Not known: High anion gap metabolic acidosis. Legal category and RRP (excl. VAT): GSL: 16s £1.88, P: 30s £3.09. Product licence number: GSL: PL 44673/0080. P: PL 44673/0185. Product licence holder: Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY, United Kingdom. Text prepared: Jan 2026.
Full information can be found in the Summary of Product Characteristics.
Otrivine Sinusitis Relief, 0.1% w/v Nasal Spray, Solution / Otrivine Blocked Nose Relief, 0.1% w/v Nasal Spray, Solution/ Otrivine Allergy Relief, 0.1% Nasal Spray. (Xylometazoline Hydrochloride). Indications: For the symptomatic relief of nasal congestion, perennial and allergic rhinitis (including hay fever) and sinusitis. Dosage: Adults, children over 12 years and the elderly: One application in each nostril up to 3 times daily. Do not exceed 3 applications daily into each nostril. Not suitable for children under 12 years. Contraindications: Hypersensitivity to xylometazoline. Trans-sphenoidal hypophysectomy or surgery exposing the dura mater, narrow-angle glaucoma, rhinitis sicca or atrophic rhinitis, phaeochromocytoma, prostatic hypertrophy, patients on MAOI treatment or who have received them in the last two weeks. Not to be used in children aged less than 12 years. Warnings and precautions: Do not take for more than seven consecutive days. Use with Caution in patients showing a strong reaction to sympathomimetic agents, with hypertension, cardiovascular disease, hyperthyroidism or diabetes mellitus and those taking tri and tetra-cyclic antidepressant treatment. Patients with long QT syndrome may be at increased risk of serious ventricular arrhythmias. Contains benzalkonium chloride, may cause irritation of the nasal mucosa. Side effects: See SmPC for full details. Common: Application site burning, nausea, headache, nasal dryness and nasal discomfort. MRSP (excl VAT): Blocked Nose Relief spray: £3.96; Allergy Relief and Sinusitis Relief spray: £5 Legal Status: GSL. Licence Number: PL 44673/0184. Licence Holder: Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY, U.K. Date of revision: Nov 2025.
Full information can be found in the Summary of Product Characteristics.
Otrivine Congestion Relief 0.1% Nasal Spray. (Xylometazoline Hydrochloride). Indications: For the symptomatic relief of nasal congestion, perennial and allergic rhinitis (including hay fever) and sinusitis. Dosage: Adults and adolescents over 12 years of age: 1 spray into each nostril, up to 3 times daily as needed. Do not exceed 3 applications daily into each nostril. Do not use in children under 12. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Trans-sphenoidal hypophysectomy or surgery exposing the dura mater, narrow-angle glaucoma, rhinitis sicca or atrophic rhinitis, phaeochromocytoma, prostatic hypertrophy, patients on MAOI treatment or who have received them in the last two weeks. Do not use in children under 12 years. Warnings and precautions: Do not take for more than seven consecutive days. Use with caution in patients showing a strong reaction to adrenergic substances, with hypertension, cardiovascular disease, hyperthyroidism or diabetes mellitus and those taking tri and tetra-cyclic antidepressant treatment. Patients with long QT syndrome may be at increased risk of serious ventricular arrhythmias. This medicine contains polyoxyl hydrogenated castor oil which may cause skin reactions. Side effects: See SPC for full details. Common: Application site burning, nausea, headache, nasal dryness and nasal discomfort. MRSP (excl. VAT): £5.42 Legal Status: GSL. Licence Number: PL 44673/0151. Licence Holder: Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY, U.K. Date of revision: October 2025.
